Uppsala, Uppsala County, Sweden, September 2025 – Jonathan Royce has been appointed as the new Chief Executive Officer at Cavidi. In his new role, he will focus on commercializing and expanding Cavidi’s groundbreaking Exazym® Reagent Kits, which have the potential to transform standard immunoassay workflows into ultra-sensitive diagnostic solutions for detecting low-abundance biomarkers.
Royce has been associated with Cavidi for more than a year, most recently serving as Director of Business & Application Development. In that role, he contributed to advancing Cavidi’s Exazym® Reagent Kits, enabling attomole-level biomarker detection while strengthening the company’s strategic positioning in the life sciences and diagnostics space.
Alongside his responsibilities at Cavidi, he is the Founder of Royce CoLabs, a consultancy providing services within the life sciences, biotechnology, med-tech, and biopharmaceutical industries. He also holds board-level responsibilities as Chairperson of the Board at Simris Group AB and as a Non-Executive Board Member at MAGic BioProcessing, where he contributes to growth and innovation in biotech and bioprocessing.
Prior to joining Cavidi, Royce was the Chief Executive Officer at Bio-Works Technologies, where he led the company for four years, enabling scientists to achieve purification goals across scales from laboratory research to large-scale bioprocessing. His leadership emphasized strategy, financing, investor relations, and international business development, reinforcing his expertise in scaling biotech companies.
Earlier in his career, Royce served as Director of the Instruments Business Unit at Vironova AB and spent over a decade at GE Healthcare, where he held leadership positions including Business Leader – Chromatography Resins, Global Product Manager – Protein A, and BioProcess Marketing Program Leader. He began his career at Millipore Corporation as a Bioprocess Engineering Consultant, gaining foundational expertise in filtration and bioprocessing technologies.
About Cavidi
Cavidi is a Swedish biotech firm pioneering Exazym®, the world’s first add-on reagent delivering ultra-sensitive detection of low-abundance biomarkers using standard immunoassay workflows. With a mission to democratize detection, Cavidi is working toward establishing Binding Oligo Ladder Detection (BOLD) as the global standard in ultra-sensitive immunoassay amplification technology by 2030. The company envisions a world where healthcare is personalized, preventative, and precise.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
